Report shows Big Pharma's patent cliff in graphic detail

The Economist's analysis of Big Pharma's patent cliff woes is worth looking at if only for the accompanying graph and its plunging sales lines for Pfizer's ($PFE) Lipitor, Sanofi ($SNY) and Bristol-Myers Squibb's ($BMY) Plavix, Novartis' ($NVS) Diovan and Merck's ($MRK) Singulair. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.